ArticleDrugs and drug candidates2025
Current Therapies and Potential Strategies for Uveal Melanoma.
Article in Drugs and drug candidates, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Precision Oncology in Ocular Melanoma: Integrating Molecular and Liquid Biopsy Biomarkers.Current issues in molecular biology · 2026Review
- Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies.BioImpacts : BI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Background/Objectives: Uveal melanoma (UM) is a rare but deadly ocular cancer. This review summarizes the characteristics of uveal melanoma and current therapeutic options for primary uveal melanoma and metastatic uveal melanoma, and introduces recent development of therapeutic strategies in preclinical animal studies and clinical trials. Methods: The literature search was conducted to identify relevant articles for UM studies. It was performed using PubMed for articles in English until March 2025. Information on clinical trials was also obtained from ClinicalTrial.gov. Results: Uveal melanoma originates from melanocytes, similar to skin melanoma. However, uveal melanoma has different mutations from skin melanoma. Thus, chemotherapy and immunotherapy, which are effective for skin melanoma, are ineffective for uveal melanoma. Current therapies for UM include radiation therapy, surgical resection, liver-directed therapies, and recently FDA-approved tebentafusp. Although a wide variety of available and newly developed therapies have been tested in clinical trials for UM, tebentafusp is the only FDA-approved therapy for metastatic UM. Given the excessive expression of vascular endothelial growth factor (VEGF) in UM patients with metastatic diseases, anti-VEGF strategies are being tested in clinical trials and pre-clinical animal models. Conclusions: This review summarizes an overview of current therapies and the development of therapeutic strategies in clinical trials and pre-clinical animal models. Despite successful control of primary tumors, 50% of UM patients still experience metastasis in the liver. Although tebentafusp improves the overall survival (OS) of a certain population of UM patients, robust strategies for preventing UM metastasis represent a critical unmet need. Further investigations of the heterogeneity of UM cells and mechanisms of UM metastasis are needed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.